（来源：冀中能源集团） 近日，华北制药华维公司凭借在大健康领域的长期深耕、创新实践与突出行业贡献，荣获2025年博鳌论坛"大健康行业AI融合健康创新企业"称号。 该公司紧扣国家工信部"5G+医疗健康应用试点项目"发展脉搏，主持实施的"5G云上健康管理项目"，使其成为河北省唯一一家人选的医药企业，并成功入 围我国第一批慢病防治典型数字产品与服务项目，以技术创新与场景落地树立区域行业标杆。 该公司着力打造多元化、智能化、精准化、一站式健康服务场景，将老字号底蕴、非遗技艺与文创理念有机融合，扎根燕赵大地、服务民生需求，为区域 经济高质量发展厚植沃土。 作为行业领军企业，该公司始终将企业发展与社会责任紧密相连。在乡村振兴领域，立足产业帮扶与民生所需，助力乡村农副产品产销对接；在公益事业 方面，持续参与文化科技卫生"三下乡"捐资助学、健康宣教等公益活动，以实际行动回馈社会各界的信任与支持；在行业发展层面，主动参与行业标准制 定、分享经营管理经验，为推动大健康行业规范化、可持续发展贡献行业力量，以实干彰显标杆企业的责任与担当。 立足新起点，该公司将持续夯实"三网合一"营销网络，精准布局全国市场、国际市场与年轻人市场；全力 ...

Core Viewpoint - North China Pharmaceutical Co., Ltd. has announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Cefprozil Tablets (0.25g) from the National Medical Products Administration, which is expected to enhance the company's product portfolio and market competitiveness [1][6]. Group 1: Drug Registration Details - The Drug Registration Certificate for Cefprozil Tablets (0.25g) was approved by the National Medical Products Administration [1]. - Cefprozil is a second-generation cephalosporin antibiotic, initially developed by Bristol-Myers Squibb in 1991, and was the first oral cephalosporin approved by the FDA for treating pediatric otitis media and sinusitis [1][2]. Group 2: Indications and Market Situation - The approved indications for Cefprozil in China include treatment for upper respiratory infections, lower respiratory infections, and skin and soft tissue infections caused by sensitive bacteria [2]. - Currently, there are 10 companies, including Huamin, that hold the Drug Registration Certificate for Cefprozil Tablets (0.25g) in China. Sales figures for Cefprozil Tablets in sample hospitals from 2023 to the first three quarters of 2025 are reported as 141.7 million, 134.99 million, and 74.22 million yuan respectively [5]. Group 3: Research and Development Investment - The cumulative R&D investment for the drug has reached 14.6458 million yuan (unaudited) [3]. Group 4: Future Prospects - Following the receipt of the Drug Registration Certificate, the company can arrange for production and market the product [4].

Core Viewpoint - North China Pharmaceutical (华北制药) announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., received the drug registration certificate for Cefprozil Tablets (0.25g) from the National Medical Products Administration [1] Group 1: Company Information - The drug Cefprozil is a second-generation cephalosporin antibiotic, first developed by Bristol-Myers Squibb in 1991 [1] - Cefprozil is the first oral cephalosporin approved by the FDA for treating pediatric otitis media and sinusitis [1] - The drug was approved for market entry in China by the National Medical Products Administration in 1999 [1] Group 2: Product Details - The approved indication for Cefprozil in China is for the treatment of mild to moderate infections caused by sensitive bacteria [1]

Core Viewpoint - North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., has received the drug registration certificate for Cefprozil tablets (0.25g) from the National Medical Products Administration, marking a significant development in its antibiotic portfolio [1] Group 1: Product Approval - The drug Cefprozil is classified as a second-generation cephalosporin antibiotic [1] - The approved indications for Cefprozil in China include treatment for mild to moderate infections caused by sensitive bacteria, such as upper respiratory infections, lower respiratory infections, and skin and soft tissue infections [1] Group 2: Indications - Specific approved indications include: 1. Upper respiratory infections: Streptococcal pharyngitis/tonsillitis, otitis media, and acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] 2. Lower respiratory infections: Acute bronchitis and exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] 3. Skin and soft tissue infections: Non-complicated infections caused by Staphylococcus aureus and Streptococcus pyogenes, with the note that abscesses may require surgical drainage [1]

Core Viewpoint - North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., has received the drug registration certificate for Cefprozil tablets (0.25g) from the National Medical Products Administration, indicating a significant regulatory approval for a new antibiotic product [1] Group 1: Product Approval - The drug Cefprozil is classified as a second-generation cephalosporin antibiotic [1] - The approved indications for Cefprozil in China include treatment for mild to moderate infections caused by sensitive bacteria, such as upper respiratory infections, lower respiratory infections, and skin and soft tissue infections [1] Group 2: Indications - For upper respiratory infections, Cefprozil is indicated for conditions like streptococcal pharyngitis/tonsillitis and acute otitis media caused by Streptococcus pneumoniae and Haemophilus influenzae [1] - In lower respiratory infections, it is used for acute bronchitis secondary to bacterial infections and acute exacerbations of chronic bronchitis [1] - The drug is also indicated for non-complicated skin and soft tissue infections caused by Staphylococcus aureus and streptococci, although abscesses typically require surgical drainage [1]

证券代码：600812 股票简称：华北制药 编号：临 2026-006 华北制药股份有限公司 关于下属公司获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，华北制药股份有限公司（以下简称"公司"）全资子公司华北 制药河北华民药业有限责任公司（以下简称"华民公司"）收到国家药品 监督管理局核准签发的头孢丙烯片（0.25g）的《药品注册证书》，现将有 关情况公告如下： 头孢丙烯(Cefprozil)属于第二代头孢菌素抗生素，该产品于 1991 年由 美国 Bristol-Myers Squibb Company 首先研制成功，商品名为施复捷，是美 国 FDA 批准的第一个可用于治疗儿童中耳炎和鼻窦炎的口服头孢菌素类 抗生素，1999 年获得中国国家药品监督管理局批准中国上市。 本品国内批准的适应症为用于敏感菌所致的下列轻、中度感染：1.上 呼吸道感染（1）化脓性链球菌性咽炎/扁桃体炎。（2）肺炎链球菌、流感 嗜血杆菌（包括产β-内酰胺酶菌株）和卡他莫拉菌（包括产β-内酰胺酶 菌株）性中耳炎及急性鼻窦 ...

Core Viewpoint - Huabei Pharmaceutical's subsidiary Huamin Company has received approval from the National Medical Products Administration for the registration of Cefprozil Tablets (0.25g), a second-generation cephalosporin antibiotic used for mild to moderate infections caused by sensitive bacteria [1] Group 1 - The registration certificate for Cefprozil Tablets was obtained on February 9, 2026, after the application was submitted in October 2024 [1] - The total research and development investment for this product amounted to 14.6458 million yuan [1]

Core Viewpoint - Huabei Pharmaceutical's subsidiary, Huamin Company, has received approval from the National Medical Products Administration for the registration of Cefprozil Tablets (0.25g), a second-generation cephalosporin antibiotic used for treating mild to moderate infections caused by sensitive bacteria [1] Group 1: Product Development - Huamin Company submitted the application for Cefprozil Tablets in October 2024 and received the acceptance number, followed by obtaining the registration certificate in February 2026 [1] - The total R&D investment for the product amounts to 14.6458 million yuan [1] Group 2: Market Context - Currently, there are 10 companies in China holding the registration certificate for Cefprozil Tablets [1] - The projected sales revenue for Cefprozil Tablets in sample hospitals in China is estimated to be 142 million yuan in 2023, 135 million yuan in 2024, and 74.22 million yuan in 2025 [1]

Core Viewpoint - The company has provided a guarantee of 140 million yuan for its subsidiary, Huamin Company, to support its working capital loan from Bank of Communications Hebei Branch, bringing the total guarantee amount to 683 million yuan as of the announcement date [1][2]. Group 1: Guarantee Details - The guarantee provided to Huamin Company is within the total limit approved at the 2024 annual shareholders' meeting and does not require further board or shareholder approval [2]. - The company has approved a total guarantee limit of 3.095 billion yuan for subsidiaries and external parties, with a specific limit of 765 million yuan for Huamin Company [1][4]. Group 2: Financial Health of Huamin Company - As of September 30, 2025, Huamin Company's debt-to-asset ratio stands at 51.03%, indicating a moderate level of financial leverage [2]. Group 3: Board's Opinion - The board believes that providing guarantees for subsidiaries is essential for their operational and strategic needs, contributing to their stable operation and long-term development [4]. Group 4: Cumulative Guarantee Situation - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to approximately 1.644 billion yuan, which is 30.50% of the audited net assets attributable to ordinary shareholders for the year 2024 [5].

Core Viewpoint - North China Pharmaceutical announced a guarantee contract with Bank of Communications Hebei Branch to support its subsidiary, Huamin Company, with a guarantee amount of 140 million yuan [1] Group 1: Guarantee Details - The guarantee provided by North China Pharmaceutical is aimed at meeting the production and operational needs of Huamin Company, facilitating its stable operation and long-term development [1] - The total guarantee amount provided by North China Pharmaceutical to Huamin Company, including this new guarantee, is 683 million yuan [1] Group 2: Financial Metrics - As of September 30, 2025, Huamin Company's debt-to-asset ratio stands at 51.03% [1] - The guarantee is within the total limit expected to be reviewed at North China Pharmaceutical's 2024 annual shareholders' meeting and is within the guarantee amount previously provided to Huamin Company [1]